Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 19/20 | 1.00 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.80 |
| ▸ | RPS6KA1 | Q15418 | 4/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.80 |
| ▸ | GRK2 | P25098 | 1/20 | 0.60 |
| ▸ | GRK5 | P34947 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8270848 | 0.92 | ROCK1 (0.85) | ROCK1RPS6KB1RPS6KA1CYP3A4CYP2D6 | |
| SCHEMBL4934940 | 0.91 | ROCK1 (1.00) | ROCK1RPS6KB1RPS6KA1CYP3A4CYP2D6 | |
| SCHEMBL4932851 | 0.89 | ROCK1 (1.00) | ROCK1RPS6KB1RPS6KA1CYP3A4CYP2D6 | |
| SCHEMBL4926469 | 0.89 | ROCK1 (1.00) | ROCK1RPS6KB1RPS6KA1CYP3A4CYP2D6 | |
| SCHEMBL4935911 | 0.88 | ROCK1 (1.00) | ROCK1RPS6KB1RPS6KA1CYP3A4CYP2D6 | |
| SCHEMBL4926348 | 0.88 | ROCK1 (1.00) | ROCK1RPS6KB1RPS6KA1CYP3A4CYP2D6 | |
| SCHEMBL4938854 | 0.88 | ROCK1 (0.84) | ROCK1RPS6KB1RPS6KA1CYP3A4CYP2D6 | |
| SCHEMBL4934024 | 0.88 | ROCK1 (1.00) | ROCK1RPS6KB1RPS6KA1CYP3A4CYP2D6 | |
| SCHEMBL4935941 | 0.86 | ROCK1 (0.81) | ROCK1RPS6KB1RPS6KA1CYP3A4CYP2D6 | |
| SCHEMBL4934671 | 0.86 | ROCK1 (0.84) | ROCK1RPS6KB1RPS6KA1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080125427-A1 | Novel Inhibitors of Rho-Kinases | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-29 | — | — | US | claimed |
| US-20080125427-A1 | Novel Inhibitors of Rho-Kinases | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080125427-A1 | Novel Inhibitors of Rho-Kinases | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080125427-A1 | Novel Inhibitors of Rho-Kinases | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-29 | — | — | US | disclosed |
| EP-1756092-A1 | NOVEL INHIBITORS OF RHO-KINASES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2006009889-A1 | NOVEL INHIBITORS OF RHO-KINASES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-01-26 | — | — | WO | disclosed |
| WO-2006009889-A1 | NOVEL INHIBITORS OF RHO-KINASES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125427-A1 | Novel Inhibitors of Rho-Kinases | ROCK1, ARHGDIB, ARHGDIA | ROCK1 1/4885RPS6KB1 261/4885RPS6KA1 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.